AAAAAA
Results:
1-15
|
Results: 15
Authors:
Khan, OA
Zvartau-Hind, M
Caon, C
Din, MU
Cochran, M
Lisak, D
Tselis, AC
Kamholz, JA
Garbern, JY
Lisak, RP
Citation: Oa. Khan et al., Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy, MULT SCLER, 7(3), 2001, pp. 185-188
Authors:
Khan, OA
Tselis, AC
Kamholz, JA
Garbern, JY
Lewis, RA
Lisak, RP
Citation: Oa. Khan et al., Appropriate design and outcome measures in multiple sclerosis clinical trials - Response, EUR J NEUR, 8(5), 2001, pp. 505-506
Authors:
Khan, OA
Tselis, AC
Kamholz, JA
Garbern, JY
Lewis, RA
Lisak, RP
Citation: Oa. Khan et al., A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis, EUR J NEUR, 8(2), 2001, pp. 141-148
Authors:
Balabanov, R
Lisak, D
Beaumont, T
Lisak, RP
Dore-Duffy, P
Citation: R. Balabanov et al., Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: Effect of glatiramer acetate (Copolymer 1), CL DIAG LAB, 8(6), 2001, pp. 1196-1203
Authors:
Lisak, RP
Bealmear, B
Benjamins, JA
Skoff, AM
Citation: Rp. Lisak et al., Interferon-gamma, tumor necrosis factor-alpha, and transforming growth factor-beta inhibit cyclic AMP-induced Schwann cell differentiation, GLIA, 36(3), 2001, pp. 354-363
Authors:
Skundric, DS
Lisak, RP
Rouhi, M
Kieseier, BC
Jung, S
Hartung, HP
Citation: Ds. Skundric et al., Schwann cell-specific regulation of IL-1 and IL-1Ra during EAN: possible relevance for immune regulation at paranodal regions, J NEUROIMM, 116(1), 2001, pp. 74-82
Authors:
Latov, N
Chaudhry, V
Koski, CL
Lisak, RP
Apatoff, BR
Hahn, AF
Howard, JF
Citation: N. Latov et al., Use of intravenous gamma globulins in neuroimmunologic diseases, J ALLERG CL, 108(4), 2001, pp. S126-S132
Authors:
Johnson, KP
Brooks, BR
Ford, CC
Goodman, A
Guarnaccia, J
Lisak, RP
Myers, LW
Panitch, HS
Pruitt, A
Rose, JW
Kachuck, N
Wolinsky, JS
Citation: Kp. Johnson et al., Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years, MULT SCLER, 6(4), 2000, pp. 255-266
Authors:
Lisak, RP
Citation: Rp. Lisak, Type I interferons and chronic inflammatory demyelinating polyneuropathy: Treatment or cause?, MUSCLE NERV, 23(3), 2000, pp. 307-309
Authors:
Zvartau-Hind, M
Din, MU
Gilani, A
Lisak, RP
Khan, OA
Citation: M. Zvartau-hind et al., Topiramate relieves refractory trigeminal neuralgia in MS patients, NEUROLOGY, 55(10), 2000, pp. 1587-1588
Authors:
Goldberg, SH
Albright, AV
Lisak, RP
Gonzalez-Scarano, F
Citation: Sh. Goldberg et al., Polymerase chain reaction analysis of human herpesvirus-6 sequences in thesera and cerebrospinal fluid of patients with multiple sclerosis, J NEUROVIRO, 5(2), 1999, pp. 134-139
Authors:
Tselis, AC
Lisak, RP
Citation: Ac. Tselis et Rp. Lisak, Multiple sclerosis - Therapeutic update, ARCH NEUROL, 56(3), 1999, pp. 277-280
Authors:
Ford, CC
Brooks, BR
Johnson, KP
Lisak, RP
Myers, LW
Panitch, HS
Rose, JW
Schiffer, RB
Vollmer, T
Weiner, LP
Wolinsky, JS
Citation: Cc. Ford et al., Sustained efficacy of glatiramer acetate for injection in a 5+ year trial of relapsing remitting MS, MULT SCLER, 4(6), 1998, pp. 521-521
Authors:
Lisak, RP
Citation: Rp. Lisak, Intravenous immunoglobulins in multiple sclerosis, NEUROLOGY, 51(6), 1998, pp. S25-S29
Authors:
Lisak, RP
Bealmear, B
Benjamins, J
Skoff, A
Citation: Rp. Lisak et al., Inflammatory cytokines inhibit upregulation of glycolipid expression by Schwann cells in vitro, NEUROLOGY, 51(6), 1998, pp. 1661-1665
Risultati:
1-15
|